Paclitaxel‐induced peripheral neuropathy (PIPN) is a common and dose‐limiting adverse event. The role of P‐glycoprotein (P‐gp) in the neuronal efflux of paclitaxel was assessed using a translational approach. SH‐SY5Y cells were differentiated to neurons and paclitaxel toxicity in the absence and presence of a P‐gp inhibitor was determined. Paclitaxel caused marked dose‐dependent toxicity in SH‐SY5Y‐derived neurons. Paclitaxel neurotoxicity was exacerbated with concomitant P‐gp inhibition by valspodar and verapamil, consistent with increased intracellular accumulation of paclitaxel. Patients with cancer treated with paclitaxel and P‐gp inhibitors had a 2.4‐fold (95% confidence interval (CI) 1.3–4.3) increased risk of peripheral neuropathy‐induced dose modification while a 4.7‐fold (95% CI 1.9–11.9) increased risk for patients treated with strong P‐gp inhibitors was observed, and a 7.0‐fold (95% CI 2.3–21.5) increased risk in patients treated with atorvastatin. Atorvastatin also increased neurotoxicity by paclitaxel in SH‐SY5Y‐derived neurons. Clinicians should be aware that comedication with P‐gp inhibitors may lead to increased risk of PIPN.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.